Cargando…

Guide to Interpreting Disease Responses in Chronic Myeloid Leukemia

With the introduction of tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia, the course of the disease has been altered from an acute, rapidly progressive terminal disorder to a serious condition with high remission rates when patients are compliant with long-term treatment. The go...

Descripción completa

Detalles Bibliográficos
Autores principales: Galinsky, Ilene, Buchanan, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093342/
https://www.ncbi.nlm.nih.gov/pubmed/25031950
_version_ 1782325707598200832
author Galinsky, Ilene
Buchanan, Susan
author_facet Galinsky, Ilene
Buchanan, Susan
author_sort Galinsky, Ilene
collection PubMed
description With the introduction of tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia, the course of the disease has been altered from an acute, rapidly progressive terminal disorder to a serious condition with high remission rates when patients are compliant with long-term treatment. The goal of therapy is to prevent transformation to the accelerated or blast crisis phases, which are associated with poor survival. Knowledge of the appropriate monitoring tests and treatment milestones, as well as the ability to interpret responses, allows advanced practitioners (APs) to effectively communicate key aspects of management to their patients. Monitoring patient responses to TKIs and identifying suboptimal responses early on offer APs the opportunity to reevaluate and adjust therapeutic treatment options. One of the causes of treatment failure is noncompliance; thus, educating patients on the importance of adhering to treatment and identifying reasons for noncompliance are of major importance. Because intolerance to TKIs may lead to discontinuation, frequent monitoring of side effects and response to treatment, open communication, patient education, and careful management are all essential in helping patients remain compliant with therapy. This review discusses the AP’s role in helping patients achieve their best response to TKI therapy and optimize their long-term outcomes.
format Online
Article
Text
id pubmed-4093342
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Harborside Press
record_format MEDLINE/PubMed
spelling pubmed-40933422014-07-16 Guide to Interpreting Disease Responses in Chronic Myeloid Leukemia Galinsky, Ilene Buchanan, Susan J Adv Pract Oncol Review Article With the introduction of tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia, the course of the disease has been altered from an acute, rapidly progressive terminal disorder to a serious condition with high remission rates when patients are compliant with long-term treatment. The goal of therapy is to prevent transformation to the accelerated or blast crisis phases, which are associated with poor survival. Knowledge of the appropriate monitoring tests and treatment milestones, as well as the ability to interpret responses, allows advanced practitioners (APs) to effectively communicate key aspects of management to their patients. Monitoring patient responses to TKIs and identifying suboptimal responses early on offer APs the opportunity to reevaluate and adjust therapeutic treatment options. One of the causes of treatment failure is noncompliance; thus, educating patients on the importance of adhering to treatment and identifying reasons for noncompliance are of major importance. Because intolerance to TKIs may lead to discontinuation, frequent monitoring of side effects and response to treatment, open communication, patient education, and careful management are all essential in helping patients remain compliant with therapy. This review discusses the AP’s role in helping patients achieve their best response to TKI therapy and optimize their long-term outcomes. Harborside Press 2012 2012-07-01 /pmc/articles/PMC4093342/ /pubmed/25031950 Text en Copyright © 2012, Harborside Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and is for non-commercial purposes.
spellingShingle Review Article
Galinsky, Ilene
Buchanan, Susan
Guide to Interpreting Disease Responses in Chronic Myeloid Leukemia
title Guide to Interpreting Disease Responses in Chronic Myeloid Leukemia
title_full Guide to Interpreting Disease Responses in Chronic Myeloid Leukemia
title_fullStr Guide to Interpreting Disease Responses in Chronic Myeloid Leukemia
title_full_unstemmed Guide to Interpreting Disease Responses in Chronic Myeloid Leukemia
title_short Guide to Interpreting Disease Responses in Chronic Myeloid Leukemia
title_sort guide to interpreting disease responses in chronic myeloid leukemia
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093342/
https://www.ncbi.nlm.nih.gov/pubmed/25031950
work_keys_str_mv AT galinskyilene guidetointerpretingdiseaseresponsesinchronicmyeloidleukemia
AT buchanansusan guidetointerpretingdiseaseresponsesinchronicmyeloidleukemia